Article
FDA OKs Netarsudil Ophthalmic Solution
Netarsudil ophthalmic solution 0.02%, is a novel once-daily eye drop believed to reduce IOP by increasing the outflow of aqueous humor through the trabecular meshwork, the main fluid drain of the eye.
Officials with the the FDA have approved netarsudil ophthalmic solution (Rhopressa, Aerie) 0.02% for the lowering of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension, according to a company press release.
Netarsudil ophthalmic solution 0.02%, is a novel once-daily eye drop believed to reduce IOP by increasing the outflow of aqueous humor through the trabecular meshwork, the main fluid drain of the eye.
Aerie CEO Vicente Anido, Jr., PhD, noted in a press statement that the company has been "preparing for commercialization for well over a year."
"We will hire our sales force of 100 sales representatives early in the first quarter of 2018, and plan to launch by mid-second quarter of 2018. As the 2018 year progresses, it is our goal to make strides in gaining formulary coverage for commercial plans, which represent approximately half of the US market. The other half of the US market is covered through Medicare Part D, and we expect our formulary presence for this market to commence in January 2019,” he said.
Reference
Aerie Pharmaceuticals Announces U.S. FDA Approval of Rhopressa (netarsudil ophthalmic solution) 0.02% for the Lowering of Elevated Intraocular Pressure in Patients with Open-Angle Glaucoma or Ocular Hypertension [news release]. Irvine, Calif. Aerie website. http://investors.aeriepharma.com/news-releases/news-release-details/aerie-pharmaceuticals-announces-us-fda-approval-rhopressar. Accessed Dec. 18, 2017.
